The Dexcom CEO will lead the lobbying group’s sector representing diabetes tech companies around the world.

The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be ...

The S&P 500 closed barely higher Feb. 13, with technology and communications services down on nagging fears of AI-disruption but equities drew support from optimism that cooling ...

Senseonics SENS recently announced the full availability of its long-term, implantable Continuous Glucose Monitoring (CGM) system, Eversense 365, integrated with Sequel Med Tech’s twiist Automated ...

According to preliminary data, the S&P 500 gained 2.32 points, or 0.03 per cent, to end at 6,835.08 points, while the Nasdaq Composite lost 52.04 points, or 0.2 per cent, to 22,545.11. The Dow Jones ...

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes ...

Insulet stock is up on fourth-quarter results ahead of consensus, with company leaders talking about talent, technology, and ...

Jacob Steven Leach, DexCom, Inc.'s President and CEO who will summarize our recent highlights and ongoing strategic initiatives. Please note that there are also slides available related to our fourth ...

Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...

DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

DexCom Inc. DXCM shares were mostly flat in Thursday's extended trading after the company released its fourth-quarter earnings report. Here's a look at the details in the report. Watch the price DXCM ...